Abstract
Parkinson’s disease is a common progressive neurodegenerative disorder presenting with characteristic motor symptoms. Non-motor dysfunctions and therapyrelated complications frequently develop, but are often underdiagnosed and undertreated. Levodopa- induced dyskinesia and impulse control disorders are suggested to share pathophysiological processes and m a y be related to alterations of the glutamatergic neurotransmission. Anti- glutamatergic interventions are therefore worth considering: several lines of evidence already indicate their beneficial effect. The kynurenine pathway offers the endogenous glutamate receptor antagonist kynurenic acid, which may act as a promising candidate for future drug development with the aim of assessment of the motor symptoms and therapy-related complications of Parkinson’s disease.
Keywords: Parkinson’s disease, kynurenic acid, neuroprotection, NMDA receptor, glutamate, levodopa-induced dyskinesia, excitotoxicity.
Current Medicinal Chemistry
Title:Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Volume: 23 Issue: 9
Author(s): Zsófia Majláth, József Toldi, Ferenc Fülöp and László Vécsei
Affiliation:
Keywords: Parkinson’s disease, kynurenic acid, neuroprotection, NMDA receptor, glutamate, levodopa-induced dyskinesia, excitotoxicity.
Abstract: Parkinson’s disease is a common progressive neurodegenerative disorder presenting with characteristic motor symptoms. Non-motor dysfunctions and therapyrelated complications frequently develop, but are often underdiagnosed and undertreated. Levodopa- induced dyskinesia and impulse control disorders are suggested to share pathophysiological processes and m a y be related to alterations of the glutamatergic neurotransmission. Anti- glutamatergic interventions are therefore worth considering: several lines of evidence already indicate their beneficial effect. The kynurenine pathway offers the endogenous glutamate receptor antagonist kynurenic acid, which may act as a promising candidate for future drug development with the aim of assessment of the motor symptoms and therapy-related complications of Parkinson’s disease.
Export Options
About this article
Cite this article as:
Majláth Zsófia, Toldi József, Fülöp Ferenc and Vécsei László, Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System, Current Medicinal Chemistry 2016; 23(9) . https://dx.doi.org/10.2174/0929867323666160212121915
DOI https://dx.doi.org/10.2174/0929867323666160212121915 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Effectiveness of Treatments for Cocaine Dependence in Schizophrenic Patients: A Systematic Review
Current Neuropharmacology The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Non-Antidepressant Treatment of Generalized Anxiety Disorder
Current Clinical Pharmacology Genetic Anomalies of the Respiratory Tract
Current Respiratory Medicine Reviews Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Discovery of MAO-B Inhibitors - Present Status and Future Directions Part I: Oxygen Heterocycles and Analogs
Mini-Reviews in Medicinal Chemistry Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review
Current Psychiatry Reviews Levodopa in Parkinson’s Disease: Current Status and Future Developments
Current Neuropharmacology New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease
Current Medicinal Chemistry Off-Label Trazodone Prescription: Evidence, Benefits and Risks
Current Pharmaceutical Design The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors
CNS & Neurological Disorders - Drug Targets Sleep in Interstitial Lung Disease
Current Respiratory Medicine Reviews A Review of Voltammetric Methods for Determination of Dopamine Agonists
Current Analytical Chemistry Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Current Neuropharmacology